Description
PP04 Limitations of CLL-1 (CLEC12A) as a putative marker of leukemic stem cells in acute myeloid leukemia
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: PP04 Limitations of CLL-1 (CLEC12A) as a putative marker of leukemic stem cells in acute myeloid leukemia
€3.03
